Pacific Shuanglin Bio pharmacy Co Ltd Asset Resilience Ratio
Pacific Shuanglin Bio pharmacy Co Ltd asset resilience ratio. Pacific Shuanglin Bio pharmacy Co Ltd (000403) has an Asset Resilience Ratio of 2.66% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 000403 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pacific Shuanglin Bio pharmacy Co Ltd (1996–2025)
Asset resilience ratio of Pacific Shuanglin Bio pharmacy Co Ltd from 1996 to 2025. This chart shows how Pacific Shuanglin Bio pharmacy Co Ltd's Asset Resilience Ratio has changed over time. Read 000403 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pacific Shuanglin Bio pharmacy Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Pacific Shuanglin Bio pharmacy Co Ltd (000403) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥259.80 Million | 2.66% |
| Total Liquid Assets | CN¥259.80 Million | 2.66% |
Asset Resilience Insights
- Limited Liquidity: Pacific Shuanglin Bio pharmacy Co Ltd maintains only 2.66% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pacific Shuanglin Bio pharmacy Co Ltd Industry Peers by Asset Resilience Ratio
Compare Pacific Shuanglin Bio pharmacy Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Pacific Shuanglin Bio pharmacy Co Ltd Asset Resilience Ratio by Year (1996–2025)
Pacific Shuanglin Bio pharmacy Co Ltd asset resilience ratio by year from 1996 to 2025. The table below shows the annual Asset Resilience Ratio data for Pacific Shuanglin Bio pharmacy Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.69% | CN¥254.39 Million ≈ $37.22 Million |
CN¥9.47 Billion ≈ $1.39 Billion |
-0.37pp |
| 2024-12-31 | 3.06% | CN¥282.70 Million ≈ $41.37 Million |
CN¥9.25 Billion ≈ $1.35 Billion |
-1.85pp |
| 2023-12-31 | 4.91% | CN¥423.34 Million ≈ $61.95 Million |
CN¥8.63 Billion ≈ $1.26 Billion |
-0.39pp |
| 2022-12-31 | 5.29% | CN¥422.44 Million ≈ $61.82 Million |
CN¥7.98 Billion ≈ $1.17 Billion |
+1.99pp |
| 2021-12-31 | 3.30% | CN¥234.21 Million ≈ $34.27 Million |
CN¥7.09 Billion ≈ $1.04 Billion |
+2.93pp |
| 2017-12-31 | 0.38% | CN¥5.00 Million ≈ $731.66K |
CN¥1.32 Billion ≈ $193.24 Million |
+0.37pp |
| 2010-12-31 | 0.01% | CN¥50.10K ≈ $7.33K |
CN¥925.41 Million ≈ $135.42 Million |
+0.00pp |
| 2009-12-31 | 0.00% | CN¥47.45K ≈ $6.94K |
CN¥1.25 Billion ≈ $183.18 Million |
+0.00pp |
| 2008-12-31 | 0.00% | CN¥28.10K ≈ $4.11K |
CN¥1.21 Billion ≈ $177.76 Million |
-0.10pp |
| 2007-12-31 | 0.10% | CN¥1.69 Million ≈ $246.60K |
CN¥1.66 Billion ≈ $242.84 Million |
+0.07pp |
| 2006-12-31 | 0.03% | CN¥566.03K ≈ $82.83K |
CN¥1.71 Billion ≈ $249.56 Million |
0.00pp |
| 2005-12-31 | 0.03% | CN¥716.11K ≈ $104.79K |
CN¥2.08 Billion ≈ $304.74 Million |
-0.06pp |
| 2004-12-31 | 0.10% | CN¥2.05 Million ≈ $300.28K |
CN¥2.12 Billion ≈ $309.58 Million |
-0.43pp |
| 2003-12-31 | 0.53% | CN¥11.86 Million ≈ $1.74 Million |
CN¥2.24 Billion ≈ $327.93 Million |
+0.44pp |
| 2002-12-31 | 0.09% | CN¥1.34 Million ≈ $196.17K |
CN¥1.54 Billion ≈ $226.02 Million |
-4.33pp |
| 1996-12-31 | 4.42% | CN¥14.62 Million ≈ $2.14 Million |
CN¥330.76 Million ≈ $48.40 Million |
-- |
About Pacific Shuanglin Bio pharmacy Co Ltd
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen… Read more